Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
HIV-Associated Lymphoid Neoplasms
share announcement

HIV-Associated Lymphoid Neoplasms

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Infectious Agents and Cancer".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 691

Special Issue Editor

Dr. José-Tomás Navarro

E-Mail Website
Guest Editor
1. Lymphoid Neoplasms Group, Josep Carreras Leukaemia Research Institute, Can Ruti Campus, 08916 Badalona, Spain
2. Department of Hematology, Institut Català d’Oncologia-Germans Trias i Pujol Hospital, 08916 Badalona, Spain
3. Department of Medicine, Universitat Autònoma de Barcelona, 08916 Badalona, Spain
Interests: lymphoma; virus; etiopathogenesis; treatment; prognosis; Epstein–Barr virus; HIV; HHV-8; HTLV-I; HCV
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Following the introduction of combined antiretroviral therapy (cART), the incidence of HIV-associated lymphomas, like other AIDS-related neoplasms, has decreased. However, lymphoma is still an important cause of morbidity and mortality among people with HIV (PWH). Moreover, in recent years, the incidence rates of some lymphoma subtypes, such as Burkitt and Hodgkin’s lymphoma, have increased. When treated with the same standard therapies, the prognosis of lymphomas affecting PWH is similar to that of the general population. Although there is information about the etiopathogenesis and the role of other viruses in the development of HIV-related lymphomas, there is still a need for studies to unveil the genetic alterations involved in the development of these lymphomas that have not been discovered as of yet.

The aim of this Special Issue of Cancers is to focus on the different aspects of HIV-associated lymphomas and other lymphoid neoplasms, including their pathogenesis, epidemiology, clinical features, and prognosis. This Special Issue welcomes reviews, as well as original research articles.

Dr. José-Tomás Navarro
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • B-cell lymphoma
  • HIV
  • AIDS
  • Epstein–Barr virus
  • epidemiology
  • pathogenesis
  • prognosis

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 862 KiB  
Article
Long-Term Survival Rates and Treatment Trends of Burkitt Lymphoma in Patients with HIV—A National Cancer Database (NCDB) Study
by Clare M. Wieland, Ashley M. Tuin, Elizabeth J. Dort, Alexander G. Hall, Mridula Krishnan and Manasa Velagapudi
Cancers 2024, 16(7), 1397; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16071397 - 02 Apr 2024
Viewed by 587
Abstract
Background: Burkitt lymphoma (BL) accounts for 10–35% of AIDS-defining lymphoma in people with HIV (PWH). Previous research consisting of smaller cohorts has shown decreased survival for HIV-associated BL. This study aims to compare overall mortality in BL patients with and without HIV, while [...] Read more.
Background: Burkitt lymphoma (BL) accounts for 10–35% of AIDS-defining lymphoma in people with HIV (PWH). Previous research consisting of smaller cohorts has shown decreased survival for HIV-associated BL. This study aims to compare overall mortality in BL patients with and without HIV, while investigating impact of treatment modalities in HIV-associated BL. Methods: Using the 2004–2019 NCDB, we identified 4312 patients with stage 3 or 4 BL who had a known HIV status and received either chemotherapy alone or chemotherapy and immunotherapy. Time to death was evaluated using Kaplan–Meier survival estimates. Risk of death was evaluated using an extended multivariable Cox model adjusted for multiple factors and with a Heaviside function for HIV status by time period (0–3 month vs. 3–60 month). Results: Of the 4312 patients included, 1514 (35%) had HIV. For months 0–3 from time of diagnosis, HIV status was not associated with a statistically significant increase in risk of death (HR = 1.04, 95% CI: 0.86, 1.26, p = 0.6648). From month 3to 60, positive HIV status was associated with a 55% increase in risk of death compared to those without HIV (95% CI: 1.38, 1.75, p < 0.0001). Further, this difference in hazard rates (0–3 vs. 3–60) was statistically significant (HR = 1.49, 95% CI: 1.22–1.82, p < 0.001). Conclusions: There is an increased mortality rate from months 3 to 60 in BL patients with HIV compared to patients without HIV. Additionally, risk of death in the first 3 months is significantly decreased by 45% in patients with HIV treated with combination chemotherapy and immunotherapy compared to patients without HIV receiving combination chemotherapy and immunotherapy, providing valuable clinical insight into treatment decision making in the care of HIV-associated BL. Full article
(This article belongs to the Special Issue HIV-Associated Lymphoid Neoplasms)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop